Herbst, Roy

Institution/Organization
Yale Cancer Center

Primary Specialty
Medical Oncology

Annual Disclosures & Policy Agreements
On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance
RSH

Disclosure of Potential Conflicts
RSH

COI Disclosure

Disclosures
AstraZeneca: Pharmaceuticals Consulting, Personal
EMD Serono Inc.: Consulting, Personal
Immunocore: Consulting, Personal
Johnson and Johnson: Consulting, Personal
Merck & Company, Inc: Consulting, Personal
Mirati Therapeutics: Consulting, Personal
Novartis Oncology: Consulting, Personal
STCube Pharmaceuticals, Inc: Consulting, Personal
Xencor, Inc: Consulting, Personal
AstraZeneca: Pharmaceuticals Research (Clinical Trials), Institutional
Genentech/Roche: Research (Clinical Trials), Institutional
Merck & Company, Inc: Research (Clinical Trials), Institutional
Immunocore Holdings Limited: Board Member (non-executive/independent), Personal
to include stock options in 2021
Junshi Biosciences Co., Ltd.: Board Member (non-executive/independent), Personal
Cybrexa Therapeutics: Consulting, Personal
eFFECTOR Therapeutics, Inc.: Consulting, Personal
Eli Lilly and Company: Consulting, Personal
I-Mab Biopharma: Consulting, Personal
Next Cure: Consulting, Personal
Bolt Biotherapeutics: Consultant, Personal, 2500 options (intrinsic value as of 4/21/2021: $0.00)

COI Disclosure Certification
RSH
Confidentiality Agreement
RSH
Standards of Conduct Agreement
RSH
IASLC’s Tax-Exempt Status
RSH

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Those institutional amounts are the research study support.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?